461-17-6

Usage

Uses

1. Used in Pharmaceutical Industry:
1-Iodo-4,4,4-trifluorobutane is used as a chemical intermediate for the synthesis of small molecule inhibitors targeting SLC15A4, which possess anti-inflammatory activity. This application is significant in the development of new drugs to combat inflammation-related conditions.
2. Used in Chemical Synthesis:
1-Iodo-4,4,4-trifluorobutane can be utilized as a building block in the synthesis of more complex organic molecules, particularly those requiring a fluorinated or iodinated butane structure. This makes it valuable in the fields of material science and specialty chemicals.
3. Used in Research and Development:
In academic and industrial research settings, 1-Iodo-4,4,4-trifluorobutane may be employed as a reagent or starting material for exploring new chemical reactions, mechanisms, or properties of fluorinated and iodinated compounds.
4. Used in Analytical Chemistry:
1-Iodo-4,4,4-trifluorobutane could be used as a reference compound or standard in analytical techniques such as gas chromatography, mass spectrometry, or nuclear magnetic resonance (NMR) spectroscopy, where its unique structure and properties can aid in the identification and quantification of similar compounds.
5. Used in Environmental Applications:
Due to its unique chemical properties, 1-Iodo-4,4,4-trifluorobutane may have potential applications in environmental chemistry, such as in the development of new methods for the detection or remediation of pollutants.
6. Used in Material Science:
1-Iodo-4,4,4-trifluorobutane could be used in the development of new materials with specific properties, such as fluoropolymers or iodo-fluoropolymers, which may have applications in various industries, including electronics, automotive, and aerospace.

InChI:InChI=1/C4H6F3I/c5-4(6,7)2-1-3-8/h1-3H2

Upstream product

• 461-18-7 4,4,4-trifluorobutanol 
• 627-31-6 1,3-Diiodopropane 
• 81290-20-2 (trifluoromethyl)trimethylsilane 
• 406-81-5 1-Bromo-4,4,4-trifluorobutane 

Downstream Products

• 461-18-7 4,4,4-trifluorobutanol 
• 1524-26-1 4,4,4-trifluorobutene 
• 485403-18-7 4-hydroxy-butyric acid trifluorobutyl ester 
• 521074-58-8 2-fluoro-4-(4,4,4-trifluorobutoxy)benzoic acid 
• 622389-90-6 triphenyl(4,4,4-trifluorobutyl)phosphonium iodide 
• 210896-85-8 bis(4,4,4-trifluorobutyl)ether 
• 199585-71-2 4-[N-Ethylsulfonyl-N-(4,4,4-Trifluorobutyl)]Amino-6-Phenyl-2,2-Dimethylchroman 
• 1046858-46-1 2-amino-4-[2,4-dichloro-6-(4,4,4-trifluorobutoxy)phenyl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic acid cyclobutylamide 
• 1373151-95-1 tert-butyl 4-({4-[5-(4,4,4-trifluorobutyl)pyridin-2-yl]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxylate 
• 639497-39-5 4-{4-[5-(4,4,4-trifluoro-butyl)-pyrazin-2-yl]benzenesulfonyl}tetrahydropyran-4-carboxylic acid tert-butyl ester 
• 639497-12-4 tert-butyl 4-({4-[5-(4,4,4-trifluorobutyl)(2-pyridyl)]phenyl}sulfonyl)-1-benzylpiperidine-4-carboxylate 
• 460-34-4 1,1,1-trifluorobutane 
• 622390-20-9 C₂₄H₃₅F₃N₂O₅S 
• 622390-47-0 C₁₆H₂₂F₃NO₂S 

Relevant academic research and scientific papers

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES

Therapeutic combinations of hepatitis B virus (HBV) vaccines and a pyridopyrimidine derivative are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. The invention provides therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection.

Quinim: A New Ligand Scaffold Enables Nickel-Catalyzed Enantioselective Synthesis of α-Alkylated ?-Lactam

Herein, we report a nickel-catalyzed reductive cross-coupling reaction of easily accessible 3-butenyl carbamoyl chloride with primary alkyl iodide to access the chiral α-alkylated pyrrolidinone with broad substrate scope and high enantiomeric excess. The current art of synthesis still remains challenging on the enantioselective α-monoalkylation of pyrrolidinones. The newly designed chiral 8-quinoline imidazoline ligand (Quinim) is crucial for maintaining the reactivity and enantioselectivity to ensure the reductive cyclization of monosubstituted alkenes for unprecedented synthesis of chiral non-aromatic heterocycles.

TOLL LIKE RECEPTOR MODULATOR COMPOUNDS

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D]pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

Fluoride-mediated selective cross-coupling reactions of alkyl halides and trimethyl(perfluoroalkyl)silanes, Me3SiRf (Rf = CF3, C2F5) in the absence of any catalysts

A temperature range of -18 °C to room temperature was found to be effective for selective fluoride-mediated cross-coupling reactions of trimethyl(perfluoroalkyl)silanes, Me3SiCF3 and Me3SiC2F5, and alkyl halides, RX (X = Br, I) in the absence of any catalyst.